Fish-Oil

Fish oil is a complex lipid extract derived from the tissue of cold-water marine fish species (principally anchovy, sardine, mackerel, herring, and menhaden) and is the predominant dietary and supplemental source of the long-chain omega-3 polyunsaturated fatty acids eicosapentaenoic acid (EPA, C20:5n-3) and docosahexaenoic acid (DHA, C22:6n-3). These two fatty acids serve as precursors for specialized pro-resolving mediators (resolvins, protectins, maresins), compete with arachidonic acid for cyclooxygenase and lipoxygenase substrate pools to shift eicosanoid production from pro-inflammatory series-2 prostaglandins and series-4 leukotrienes toward less inflammatory or anti-inflammatory series-3 prostaglandins and series-5 leukotrienes, modulate cell membrane phospholipid composition and lipid raft organization, activate the anti-inflammatory transcription factor peroxisome proliferator-activated receptor gamma (PPARgamma), signal through the G protein-coupled receptor GPR120, and influence ion channel conductance and cardiac electrophysiology. The pharmacological interest in fish oil spans more than five decades, originating with the epidemiological observations of Bang and Dyerberg in Greenland Inuit populations in the early 1970s and progressing through multiple large-scale randomized controlled trials including GISSI-Prevenzione (1999), JELIS (2007), VITAL (2019), REDUCE-IT (2019), and STRENGTH (2020). Prescription omega-3 formulations have received regulatory approval from the United States Food and Drug Administration for the treatment of severe hypertriglyceridemia (triglycerides 500 mg/dL or greater): omega-3-acid ethyl esters (Lovaza, approved 2004), icosapent ethyl (Vascepa, approved 2012), and omega-3-carboxylic acids (Epanova, approved 2014). Icosapent ethyl, a purified EPA ethyl ester, received an expanded FDA indication in 2019 for cardiovascular risk reduction in statin-treated patients with elevated triglycerides and established cardiovascular disease or diabetes, based on the REDUCE-IT trial demonstrating a 25 percent relative risk reduction in major adverse cardiovascular events. The STRENGTH trial, which tested a combined EPA and DHA carboxylic acid formulation, was terminated early for futility with no cardiovascular benefit observed, generating ongoing debate regarding the differential efficacy of EPA-only versus EPA plus DHA preparations and the potential confounding role of mineral oil placebo in REDUCE-IT. Fish oil pharmacokinetics are governed by the chemical form of the omega-3 fatty acids (triglyceride, ethyl ester, free fatty acid, or phospholipid), with triglyceride and free fatty acid forms demonstrating superior bioavailability compared to ethyl esters, particularly under low-fat dietary conditions. Absorption requires pancreatic lipase-mediated hydrolysis and micellar solubilization; peak plasma EPA and DHA concentrations are achieved at approximately 5 to 8 hours post-dose, and steady-state tissue incorporation requires 4 to 12 weeks of daily supplementation. The safety profile of fish oil at standard supplemental doses (1 to 4 grams of EPA plus DHA daily) is generally favorable, with the principal adverse events being gastrointestinal discomfort, fishy eructation, and mild prolongation of bleeding time without clinically significant hemorrhage. At pharmacological doses (4 grams daily), meta-analyses of randomized controlled trials have identified a statistically significant increase in the risk of atrial fibrillation (approximately 24 percent relative risk increase), representing the most clinically consequential safety signal in the contemporary evidence base. This monograph reviews the chemical identification and compositional analysis of fish oil; the discovery and development history from the Greenland epidemiology through modern pharmaceutical registration; the molecular pharmacology of EPA and DHA across lipid mediator, transcription factor, membrane, and ion channel mechanisms; pharmacokinetics including formulation-dependent bioavailability; preclinical pharmacology in cardiovascular, inflammatory, and cognitive animal models; the clinical evidence base across cardiovascular, inflammatory, psychiatric, and neurocognitive indications; sourcing and quality verification; reconstitution and handling; stack interactions and combinations; adverse events and safety signals; and a comparative assessment of five alternative omega-3 sources (krill oil, algal oil, icosapent ethyl, flaxseed oil, and omega-3-carboxylic acids) against fish oil on five standards (bioavailability, clinical evidence base, safety profile, cost and accessibility, and overall validation).